HCMT
SRPT icon

Highland Capital Management (Texas)’s Sarepta Therapeutics SRPT Stock Holding History

Highland Capital Management (Texas)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-665,100
Closed -$25.7M – 269
2015
Q4 		$25.7M Buy
+665,100
New +$21.6M 0.82% 33

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Highland Capital Management (Texas)'s SRPT Position: Q3 2018 in Review

Highland Capital Management (Texas) sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 4,000 shares — an estimated $529K sold.

Highland Capital Management (Texas) first reported a position in SRPT in Q4 2013 and held it in 11 quarters. The position peaked at $12.3M in Q3 2015. 345 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Highland Capital Management (Texas) reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Highland Capital Management (Texas) sold 4,000 Sarepta Therapeutics shares in Q3 2018, an estimated $529K.
  • Highland Capital Management (Texas) first reported a position in Sarepta Therapeutics in Q4 2013 and held it in 11 quarters.
  • Highland Capital Management (Texas)'s Sarepta Therapeutics position peaked at $12.3M in Q3 2015.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Highland Capital Management (Texas)'s 13F filing for Q3 2018, filed 14 Nov 2018.